Stock TLSA TIZIANA LIFE SCIENCES LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.7801 USD -7.25% Intraday chart for Tiziana Life Sciences Ltd +17.13% +39.30%
Apr. 23 Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Apr. 23 Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program MT

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 93.41 60.66
Enterprise Value (EV) 2 51.23 42.91
P/E ratio -4.01 x -3.95 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -1.87 x -2.94 x
EV / FCF -3.83 x -5.41 x
FCF Yield -26.1% -18.5%
Price to Book 2.38 x 3.08 x
Nbr of stocks (in thousands) 97,306 101,360
Reference price 3 0.9600 0.5985
Announcement Date 5/23/22 4/26/23
1USD in Million2GBP in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA 1 -8.235 -7.433 -9.916 -30.4 -27.37 -14.58
EBIT 1 -8.246 -7.445 -9.921 -30.41 -27.37 -14.59
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -8.255 -7.454 -10.01 -28.34 -26.66 -15.4
Net income 1 -6.77 -5.995 -9.323 -26.13 -23.42 -15.4
Net margin - - - - - -
EPS 2 -0.0636 -0.0470 -0.0683 -0.1546 -0.2391 -0.1517
Free Cash Flow 1 -4.179 -1.972 -3.663 -2.577 -13.38 -7.931
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 6/7/18 4/4/19 6/17/20 5/17/21 5/23/22 4/26/23
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 0.19 - 0.62 - - -
Net Cash position 1 - 3.92 - 65.3 42.2 17.8
Leverage (Debt/EBITDA) -0.0226 x - -0.0625 x - - -
Free Cash Flow 1 -4.18 -1.97 -3.66 -2.58 -13.4 -7.93
ROE (net income / shareholders' equity) -830% 943% 373% -91.9% -45.2% -50.6%
ROA (Net income/ Total Assets) -150% -128% -133% -52% -28.6% -24.2%
Assets 1 4.52 4.681 6.99 50.21 81.77 63.59
Book Value Per Share 2 -0.0100 0 -0.0400 0.3200 0.4000 0.1900
Cash Flow per Share 2 0 0.0300 0 0.3400 0.4100 0.1800
Capex 1 0 - 0 0 0.02 -
Capex / Sales - - - - - -
Announcement Date 6/7/18 4/4/19 6/17/20 5/17/21 5/23/22 4/26/23
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TIZIANA LIFE SCIENCES LTD Stock Tiziana Life Sciences Ltd
+39.30% 78.25M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TLSA Stock
  4. Financials Tiziana Life Sciences Ltd